Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Bausch Health to fork over $300 million in diabetes antitrust lawsuit

By Brian Buntz | September 10, 2021

Bausch HealthBausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold.

The plaintiffs, drug distributor companies, in the class-action suit filed in 2019 has asked U.S. District Judge William Alsup in San Francisco to approve the settlement.

The settlement would be significant for pharmaceutical industry standards, although a handful of settlements have been larger. Most notably, fen-phen agreed to pay $3.75 billion in a settlement tied to the diet drug fen-phen in 1999.

The 2019 lawsuit was titled, “Re: Glumetza Antitrust Litigation, U.S. District Court, Northern District of California, No. 19-cv-05822.”

Glumetza is an extended-release version of metformin hydrochloride, a popular type 2 diabetes treatment.

FDA approved Glumetza in 2005, which was initially marketed by Depomed (now Assertio) in conjunction with Santarus. Bausch Health eventually acquired Santarus.

Lupin Pharmaceuticals intended to launch a generic version of the drug in 2012, but the prior owners of the drug rights, Assertio and Santarus, allegedly paid to delay the generic until 2016.

Bausch Health’s stock was mostly unphased in trading today. BHC shares ticked down 0.59% to $28.45, while the S&P 500 index dipped 0.77%.

Bausch Health did not immediately respond to a request for comment.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards